Malignant Mesothelioma

Malignant Mesothelioma Recent Results in Cancer Research P.M. Schlag. H.-J Senn Series Editors. This book will cover all information about Malignant Mesothelioma some of them are below and a detail of the content is given below the book image.

• malignant mesothelioma treatment
• malignant mesothelioma symptoms
• malignant mesothelioma causes
• malignant mesothelioma prognosis
• mesothelioma definition
• malignant mesothelioma icd 10
• malignant mesothelioma radiology
• what is mesothelioma

• Mineralogy of Asbestos. 
• Introduction and Historical Background
• Geologic and Mineralogic Features 
• Distribution and Physicochemical Properties of Chrysotile 
• Distribution and Physicochemical Properties of the Amphibole Species
•  Identifcation and Characterization of Asbestos
•   Epidemiology of Mesothelioma and Historical
• Imaging of Mesothelioma
• Patterns of Presentation and Imaging Features
• Preoperative Evaluation of MPM 
• Postoperative Evaluation 
• Unresectable Disease 
•  Biopsy Techniques for the Diagnosis of Mesothelioma 
• Introduction Clinical Presentation
• Investigation of Pleural Effusion Cytology
• Investigation of Pleural Thickening with No Effusion  Percutaneous Pleural Biopsy Techniques  
• Radiologically Guided Percutaneous Pleural Biopsy
• Positron Emission Tomography (PET) CT  Thoracoscopy
• Local Anaesthetic Thoracoscopy
• Video-Assisted Thoracoscopic Surgery
• Open Biopsy Prophylactic Radiotherapy
• Pathohistological Diagnosis and Differential Diagnosis
• Iris Tischoff, Matthias Neid, Volker Neumann, and Andrea Tannapfel
• Malignant Mesothelioma of the Pleura
• Differential Diagnosis of Malignant Mesothelioma and Pleural Metastases
• Morphological Differences Immunohistochemistry
• Reactive Versus Neoplastic Mesothelial Proliferation Primary Pleural Tumours Other than 
• Malignant Mesothelioma
• Peritoneal Mesothelioma
• Malignant Mesothelioma of Tunica Vaginalis Testis
• Well-Differentiated Papillary Mesothelioma Prognosis and Predictive Factors Differential Diagnosis
• Benign Lesions  Malignant Lesions Immunohistochemistry
• Primary Peritoneal Carcinoma/Metastases of Serous
  Ovarian Cancer Versus Malignant Peritoneal Mesothelioma
• Mesothelioma and Analysis of Tissue Fiber
• Volker Neumann, Stefan Löseke, and Andrea Tannapfel
• Techniques for Analysis of Pulmonary Mineral-Fiber Content
• Lung Tissue Digests
• Methods for Mineral Fiber Analysis
• Light Microscopy (LM)
• Electron Microscopy
• Comparability of Results Generated by Light or Electron Microscopy
• Reference Population and Background Lung Asbestos Burden
• Asbestos Bodies and Fiber Counting 
• Asbestos Lung Tissue Content in Patients with Mesothelioma 
• Light Microscopy 
• Electron Microscopy
• Asbestos Content and Fiber Dimensions in Pleural Samples
• Asbestos Bodies and Fiber Burden of the Lung
• Latency Period and Mean Age at Diagnosis of Mesothelioma
• Clearance and Biopersistence of Asbestos Fibers
• Carcinogenic Potency of Asbestos Fibers
• Peritoneal Mesothelioma
• Asbestos-Associated Mesothelioma   and Other Possible Causes of Malignant Mesothelioma
• Threshold or Cut-off Level
• Surgical Therapy of Mesothelioma
• Diagnosis of Mesothelioma
• Video-Assisted Thoracoscopy
•  Staging Laparoscopy Mediastinoscopy Thoracoscopy  Endoscopic Staging Palliative Surgery 
• Pleural Drainage  Pleurectomy  Cytoreductive Surgery  Extrapleural Pneumonectomy (EPP)  
• Pleurectomy/Decortication (P/D)
• Intrapleural Therapies
• Extrapleural Pneumonectomy Versus
• Pleurectomy/Decortication
• Does Cytoreductive Surgery Improve Survival?
• Chemotherapy and Radiotherapy for Mesothelioma
• Radiotherapy  Radical Radiotherapy
• Prophylactic Radiotherapy
• Systemic Therapies for Malignant Pleural Mesothelioma Systemic Chemotherapy
• Targeted Therapies
• Immunomodulators, Gene Therapy and Cell Therapy
• Genetics and Molecular Biology of Mesothelioma.
• Apoptosis as a Tumor Suppressor Mechanism Key Alterations in the Core Apoptosis Signaling in Mesothelioma
• Regulation of the Intrinsic (Mitochondrial)
  Apoptosis Pathway in Mesothelioma
• Extrinsic Apoptosis Pathway Regulation in Mesothelioma
• Inhibitors of Apoptosis in Mesothelioma
• Tumor Suppressor Loss in Mesothelioma
  Loss of nf2 Is Frequent in Mesothelioma  
• NF2 Encodes the Tumor Suppressor Merlin PLZF Is  a Novel Tumor Suppressor in Mesothelioma
• Therapeutic Inhibition of Survival Pathways
• PI3K/AKT/mTOR Axis in Mesothelioma
• HGF/cMET Pathway Is Activated in Mesothelioma
• WNT Pathway Activation in Mesothelioma
• Estrogen Receptor Beta  Therapeutic Reactivation of Tumor Suppressors Epigenomic 
• Dysregulation in Mesothelioma  Targeting the Mesothelioma Epigenome via Inhibition of 
• Histone DeacetylasesTargeting the Ubiquitin Proteasome Synthetic Lethal Strategies Early 
• Stages of Mesothelioma, Screening  and Biomarkers
• Sonja Klebe and Douglas W. Henderson
• Early-Stage Malignant Mesothelioma, Including the Concept of Mesothelioma In Situ and the  
• Distinction from Reactive Mesothelial Hyperplasia  Biomarkers for Early-Stage Epithelioid  Malignant
• Mesothelioma Versus Reactive Mesothelial Hyperplasia  Epithelial Membrane Antigen (EMA) 
• X-Linked Inhibitor of Apoptosis Proteins (XIAP)
• P-Glycoprotein (P-170) Neural Cell Adhesion Molecules NCAMs): CD56
• Screening for Malignant Mesothelioma and Prognostic
• Biomarkers: Serum Levels of Soluble Mesothelin-Related Proteins (SMRPs), Osteopontin 
• (OPN),  Megakaryocyte
• Potentiating Factor (MKPF) and CA125
• Introductory Remarks on Screening for Malignant Mesothelioma Radiological Screening for 
• MMSoluble Mesothelin-Related Proteins (SMRPs)
• Serum Osteopontin OPN) LevelsMegakaryocyte Potentiating Factor (MKPF)  Aquaporins and 
• Malignant Mesothelioma